A case series: evaluation of the metabolic safety of aripiprazole
about
Management of antipsychotic-related weight gainAntipsychotic treatments for the elderly: efficacy and safety of aripiprazole.Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting.Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trialThe prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Diabetic control and atypical antipsychotics: a case report.Using Routine Hemoglobin A1c Testing to Determine the Glycemic Status in Psychiatric Inpatients.Weight considerations in psychotropic drug prescribing and switching.Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists.Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia.Evaluation of buspirone on streptozotocin induced type 1 diabetes and its associated complications.Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based cohort study.Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome.Evaluation of venlafaxine on glucose homeostasis and oxidative stress in diabetic mice.
P2860
Q24610124-0DA71738-BF7B-43A6-AB44-6F2EA0288134Q33755676-92EBCF59-FCD3-4EE9-81E3-90C2A65D74D5Q34033259-7CAE7874-886E-4A5B-A34A-3C222AE6D7E8Q34174609-D0A2E0BF-E7A5-46A5-9E3C-503344FCA7E4Q36474147-D8F9EB80-B242-4E43-9327-CF1D29CAB0D0Q36664112-52D097CE-C08C-4499-8AA5-D243E23D1D33Q37079080-B3E4959D-1AB0-45EC-A246-60FB4AAA2AA9Q37163569-B20E775E-0A3E-43B0-BB5B-E0D51BCDFD99Q37721692-D14984EC-FC62-46CE-80CD-9D0734038C43Q38151453-470928E7-077A-4B5B-B7EC-9ADDDFED4029Q38352080-88EB6268-735E-45B6-834B-5E755B7F894DQ41587365-A4B7D8B7-2408-47DD-A593-7F9C1FCCF849Q41921965-81E615C4-D1A2-4DEF-BD14-545C010BC7ABQ44852184-F4481FBA-A0F9-4F43-ABBE-25D72F798C11Q46756223-53D7D8F2-1A9F-4A08-AA77-CB48C3BEAE3BQ47152270-1EED6379-458F-4E70-8863-112AE8AE8AB9Q48453853-203D49CE-3320-4A67-8901-7852E1B264E0
P2860
A case series: evaluation of the metabolic safety of aripiprazole
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A case series: evaluation of the metabolic safety of aripiprazole
@en
type
label
A case series: evaluation of the metabolic safety of aripiprazole
@en
prefLabel
A case series: evaluation of the metabolic safety of aripiprazole
@en
P2093
P2860
P356
P1476
A case series: evaluation of the metabolic safety of aripiprazole
@en
P2093
Andre Scheen
Dominique Van Eyck
Linda Hanssens
Marc De Hert
Martien Wampers
Ruud van Winkel
P2860
P304
P356
10.1093/SCHBUL/SBL037
P407
P577
2006-08-29T00:00:00Z